Journal: Journal of Magnetic Resonance Imaging

Article Title: Current State of MRI ‐Guided Endovascular Arterial Interventions: A Systematic Review of Preclinical and Clinical Studies

doi: 10.1002/jmri.28205

Figure Lengend Snippet: Study Characteristics and Outcomes

Article Snippet: Kos et al , 1.5 T , GRE T1‐FLASH, TR/TE: 8.12/5.24 msec, FA: 21°, ST: 5 mm, FR: 2/3 fps , Guidewire (Biotronik Vascular Intervention, Buelach, Switzerland) with iron oxide nanoparticles (MagnaFy; MagnaMedics GmbH, Aachen, Germany), balloon catheter (Pheron, Biotronik), self‐expandable stent (Astron, Biotronik), self‐expandable stent (Wallstent; Boston Scientific, Maple Grove, MN).

Techniques: Imaging, Migration, Dissection, Marker, Sequencing, Sterility

Journal: Journal of Magnetic Resonance Imaging

Article Title: Current State of MRI ‐Guided Endovascular Arterial Interventions: A Systematic Review of Preclinical and Clinical Studies

doi: 10.1002/jmri.28205

Figure Lengend Snippet: MRI Field Strength, Sequence, and Endovascular Device Types Used in the Included Studies

Article Snippet: Kos et al , 1.5 T , GRE T1‐FLASH, TR/TE: 8.12/5.24 msec, FA: 21°, ST: 5 mm, FR: 2/3 fps , Guidewire (Biotronik Vascular Intervention, Buelach, Switzerland) with iron oxide nanoparticles (MagnaFy; MagnaMedics GmbH, Aachen, Germany), balloon catheter (Pheron, Biotronik), self‐expandable stent (Astron, Biotronik), self‐expandable stent (Wallstent; Boston Scientific, Maple Grove, MN).

Techniques: Sequencing, Combined Bisulfite Restriction Analysis Assay, Polymer

Journal: Journal of Magnetic Resonance Imaging

Article Title: Current State of MRI ‐Guided Endovascular Arterial Interventions: A Systematic Review of Preclinical and Clinical Studies

doi: 10.1002/jmri.28205

Figure Lengend Snippet: Challenges Related to MRI‐Guided Endovascular Interventions and the Number of Articles Discussing the Challenges

Article Snippet: Kos et al , 1.5 T , GRE T1‐FLASH, TR/TE: 8.12/5.24 msec, FA: 21°, ST: 5 mm, FR: 2/3 fps , Guidewire (Biotronik Vascular Intervention, Buelach, Switzerland) with iron oxide nanoparticles (MagnaFy; MagnaMedics GmbH, Aachen, Germany), balloon catheter (Pheron, Biotronik), self‐expandable stent (Astron, Biotronik), self‐expandable stent (Wallstent; Boston Scientific, Maple Grove, MN).

Techniques: Imaging, Marker, Control, Sterility

Journal: Frontiers in Molecular Neuroscience

Article Title: PGC-1α Signaling Increases GABA(A) Receptor Subunit α2 Expression, GABAergic Neurotransmission and Anxiety-Like Behavior in Mice

doi: 10.3389/fnmol.2021.588230

Figure Lengend Snippet: List of primer sequences.

Article Snippet: These included antibodies against GABARα2 (diluted 1:1,000; no. 822-GA2C, PhosphoSolutions, Aurora, CO, United States), GABARα1 (diluted 1:1,000; no. 812-GA1N, PhosphoSolutions, United States), PGC-1α (1:2000; Merck Millipore, Billerica, MA, United States), and ß-actin that was used as control (1:1,000; no 2066, Sigma).

Techniques:

Journal: Frontiers in Molecular Neuroscience

Article Title: PGC-1α Signaling Increases GABA(A) Receptor Subunit α2 Expression, GABAergic Neurotransmission and Anxiety-Like Behavior in Mice

doi: 10.3389/fnmol.2021.588230

Figure Lengend Snippet: GABA-A receptor α2 subunit expression is increased in PGC-1α transgenic mice. (A) Quantitative PCR was performed as described in the section “Materials and Methods” using cDNA from the hippocampus (HC) and frontal cortex (CX) of 4-month old wild-type (Wt) and PGC-1α transgenic mice (Tg). Quantifications were done as described in the section “Materials and Methods” using Gapdh expression as control and Student’s t -test. Values are means ± SEM, n = 7. Left, HC; GABARα2 mRNA levels increased in the hippocampus of Tg mice compared with Wt animals. * p < 0.05. Right, CX. In the frontal cortex the difference was not significant between groups. p = 0.058. (B) Immunoblottings using lysates from the hippocampus (HC) and frontal cortex (CX) of 3-month old Wt and PGC-1α Tg mice were done using anti-GABARα2 antibody and anti-β-actin antibody as control. GABARα2 is shown at 52 kDa (upper lanes) and β-actin at 42 kDa (lower lanes). Quantification of GABARα2 levels was done using β-actin as control and Student’s t -test. Values are means ± SEM. n = 9 for HC, n = 6 for CX. ** p < 0.01 for Tg vs. Wt. (C) Representative immunoblots showing GABARα2 at 52 kDa and β-actin as a control at 42 kDa. (D) Immunoblottings were done using anti-GABARα1 antibody and anti-β-actin antibody as control. Left, HC; Right, CX. GABARα1 levels were quantified using β-actin as control and Student’s t -test. Values are means ± SEM. n = 7 for HC, n = 6 for CX. There was no significant difference between groups. (E) Representative immunoblots showing GABARα1 at 52 kDa (upper lane) and β-actin as a control at 42 kDa (lower lanes).

Article Snippet: These included antibodies against GABARα2 (diluted 1:1,000; no. 822-GA2C, PhosphoSolutions, Aurora, CO, United States), GABARα1 (diluted 1:1,000; no. 812-GA1N, PhosphoSolutions, United States), PGC-1α (1:2000; Merck Millipore, Billerica, MA, United States), and ß-actin that was used as control (1:1,000; no 2066, Sigma).

Techniques: Expressing, Transgenic Assay, Real-time Polymerase Chain Reaction, Control, Western Blot